The practical result, in our clinical experience, is that patients with a subacute tendinopathy that has stalled at 6 to 12 weeks of physical therapy tend to notice a meaningful change in pain level and range of motion within 3 to 4 weeks of starting a BPC-157 protocol
These are often promoted as preferable to traditional tablets as they claim to bypass the digestive system
It is not intended for human or veterinary use, and is not intended to diagnose, treat, cure, or prevent any medical condition or disease
At Mirror Plastic Surgery, BPC-157 is often included in the Glow Stack with TB500 and GHK-CU to support inflammation control and tissue repair
Promotes Blood Vessel Growth
Peptide Vials Based on a 16 mg vial and a representative 4 mg daily dose, one vial gives about 4 doses